Drug Discovery Chemistry is a dynamic conference and networking event for drug discovery scientists working in pharma, biotech, and academia. One of the few events that reflects the new cross-functional and collaborative nature of drug discovery, our speakers and attendees are comprised primarily of pharma and biotech scientists, as well as key academic thought leaders working in translational research. Discussions of chemical tools and approaches to meet the practical (not theoretical) challenges of drug discovery are front and center.
The 2025 program featured a plenary keynote, Small Molecule Control of the Undruggable Proteome: PROTACs and Beyond, from Dr. Craig M. Crews of Yale University, a pioneer in targeted protein degradation and inventor of PROTACs. In addition, you'll hear 15+ cutting-edge presentations from top pharma including AstraZeneca, Amgen, Bayer, Genentech, Janssen, Johnson & Johnson, Merck KGaA, Novartis, Roche, and Sanofi. Talks will cover AI-driven lead optimization, fragment-based design, DEL screening, protein degradation, and more—offering attendees a practical view of how today’s most promising strategies are being applied across therapeutic areas.